Casey Patrick John sold $89K of LEGN

Casey Patrick John sold 6,000 shares of Legend Biotech Corp (LEGN) at $14.80 on 2026-06-30.

Original reporting
SEC EDGAR · Casey Patrick John
Published Jul 2, 2026, 4:00 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Aug 6, 2026, 7:44 AM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
AlphAI market briefInsider activity
Primary signal
$LEGN
Neutral
medium confidence
Mentioned
$LEGN
Relevance
3/10
AlphAI data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$LEGNNeutralLow
01

Why it matters

The disclosure indicates an open-market sale of 6,000 shares at $14.80 on June 30, with holdings after the transaction of 48,604 shares.

02

Market read

Traders may monitor insider activity for sentiment, but this filing alone does not provide a new operational or financial catalyst.

03

What to watch

The article provides only the sale size and post-transaction holdings, not total insider ownership changes, sale history, or whether other insiders sold/bought around the same time.

Relevance 3/10Novelty 3/10Timing: Form 4 filed July 2, covering a June 30 sale.

Background

This is an SEC Form 4 insider transaction disclosure for Legend Biotech director Casey Patrick John.

Company-level read

Ticker impact

$LEGNNeutralMedium confidence
Context

Legend Biotech director Casey Patrick John sold 6,000 shares in an open-market transaction for about $88.8K, per Form 4 filed July 2.

Expected impact

Low near-term impact; any reaction is likely limited to short-lived sentiment around insider selling.

Evidence & confidence

The filing discloses a small-to-moderate dollar value sale by a director, with no accompanying company-specific catalyst (earnings, guidance, deal, or regulatory action).

Market effects

Minimal; this is company-specific insider transaction data, not a sector-wide signal.

None.

None.

Counterpoint

Insider sales are often planned for diversification or liquidity needs; the absence of a stated 10b5-1 plan does not necessarily imply negative information.

Key entities

  • Legend Biotech Corp

    Company whose director insider sale is disclosed on Form 4.

  • Casey Patrick John

    Director who sold 6,000 shares in an open-market transaction.

Full insider trading history

This story covers one filing. See everything behind it: every insider buy and sell on record, 10b5-1 plans, late filings, and which officers and directors are trading.

Related articles

$LEGNMedAI 8/10

Legend Biotech (LEGN) Q3 2026 Earnings Call Transcript

Legend Biotech (LEGN) reported Q3 2026 earnings, with CARVYKTI net trade sales up 36% YoY to $710M. Growth driven by U.S. and international adoption. The company presented long-term data supporting CARVYKTI's use in earlier multiple myeloma lines and received FDA clearance for LB2501. Legend Biotech aims for profitability in 2026 and has $853M in cash reserves.

$LEGNMedAI 8/10

Legend Biotech Corp (LEGN) Q3 2026 Earnings Call Highlights: CARVYKTI Sales Jump 36%

Legend Biotech (LEGN) reported a 36% increase in CARVYKTI sales for Q3 2026, but U.S. sales were flat. Management noted slower-than-expected U.S. growth and launch delays in ex-U.S. markets. R&D expenses declined 16% year-over-year, but future spending may increase. CARVYKTI's U.S. sales mix shifted toward earlier lines, and the company expects double-digit growth in 2027. LB2501 dose level 3 showed lower efficacy than dose level 2, and there were no updates on LB2505.

$LEGNMed

What Legend Biotech (LEGN) Said on Its Q3 Earnings Call

Legend Biotech (LEGN) reported a 32% year-over-year revenue increase, with adjusted net income of $55.6M. CEO Ingrid Zhang expects CARVYKTI to generate over $5B in peak sales. The company improved gross margins and reduced R&D expenses. Legend also received FDA clearance for a clinical study of LB2501 and shared positive interim data. The company remains debt-free with $853M in cash equivalents.

$LEGNHigh

Why is Legend Biotech stock sliding today?

Legend Biotech (LEGN) stock fell 13.2% pre-market after reporting a Q3 2026 GAAP loss of $0.13 per share, missing estimates. Revenue of $359.5M beat expectations, but license revenue declined. The company announced a new CEO and FDA clearance for LB2501, but these were overshadowed by the earnings miss and broader market declines.

$LEGNMed

Legend Biotech shares fall 2% despite revenue beat

Legend Biotech (LEGN) reported Q3 2026 revenue of $359.5M, beating estimates. Shares fell 2.18% despite results. Collaboration revenue rose to $353.2M, driven by CARVYKTI sales. Net income was $51.7M, reversing a prior-year loss. R&D and admin expenses declined. FDA cleared IND for LB2501. Cash reserves were $853M.